Medivir AB and Daewoong Pharmaceutical Co. Ltd. have decided to discontinue development of hepatitis B compound, MIV-210, based on a joint decision.
Under the collaboration Daewoong was responsible for R&D. While MIV-210 demonstrated competitive antiviral activity, like other drugs of this class, it did not completely eradicate HBV. Taking into consideration the commercial environment for HBV drugs, with the current standard of care approaching generic status, a robust cure profile is needed, which would require combination with other drugs.
“In light of the characteristics MIV-210 could offer for the treatment of Hepatitis B, we have together with our partner Daewoong decided to abandon the development activities with MIV-210”, said Maris Hartmanis, chief executive officer, Medivir AB.
Medivir, Daewoong Discontinue Hep B Alliance
Published September 6, 2013
blog comments powered by Disqus